Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now.
On June 7, Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) and set a price target of $101
The firm’s price target implies an additional 95% upside from current levels. In addition to Prakhar Agrawal, BMO Capital analyst Evan Seigerman reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5 and set a target price of $145. The analyst believes that the company’s most advanced weight-loss drug, aleniglipron, showed strong results in clinical trials.
The data showed significant and sustained weight loss, along with a favorable safety profile with no major liver concerns. These positive results suggest aleniglipron could become one of the leading oral obesity treatments on the market. In addition to weight loss, the drug showed benefits such as lowering blood pressure and reducing inflammation without causing a significant increase in heart rate.